Prevention of doxorubicin-induced cardiomyopathy by reduced glutathione.

Villani, F; Galimberti, M; Zunino, F; Monti, E; Rozza, A; Lanza, E; Favalli, L; Poggi, P

Villani, F; Galimberti, M; Zunino, F; Monti, E; Rozza, A; Lanza, E; Favalli, L; Poggi, P.

Affiliation

Villani F; Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.

Cancer Chemother Pharmacol ; 28(5): 365-9, 1991.

Article in En | MEDLINE | ID: mdl-1914080

Subject(s)

Cardiomyopathies/prevention & control; Doxorubicin/toxicity; Glutathione/therapeutic use; Animals; Cardiomyopathies/chemically induced; Cardiomyopathies/metabolism; Dose-Response Relationship, Drug; Doxorubicin/administration & dosage; Drug Evaluation, Preclinical; Electrocardiography/drug effects; Female; Glutathione/metabolism; Myocardium/chemistry; Myocardium/metabolism; Rats; Rats, Inbred Strains; Sulfhydryl Compounds/analysis; Sulfhydryl Compounds/metabolism; Time Factors

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Doxorubicin / Glutathione / Cardiomyopathies Type of study: Prognostic_studies Language: En Journal: Cancer Chemother Pharmacol Year: 1991 Type: Article Affiliation country: Italy

Search on Google

Add to My VHL

XML

PubMed Links